NASH+
Everolimus-eluting coronary stent
Reg. cert. РЗН 2025/25736 dated 24.06.2025
Description

The NASH+ everolimus-eluting coronary stent is intended to increase the lumen diameter of the coronary vessels in patients with symptomatic coronary artery disease, including patients with acute myocardial infarction and patients with concomitant diabetes mellitus, caused by de novo focal lesions of the native coronary artery.
- Ultra-thin struts (65 µm) reduce the risk of late stent thrombosis
- Ultra-low crossing profile (~1.0 mm) for improved flexibility and deliverability
- Increased radial strength gives reliable vessel-wall support and reduces recoil (<5%) for a stable result after implantation
- A thin 3 µm bioresorbable polymer coating reduces the risk of vessel inflammation
- The coating technology keeps the polymer intact after stent expansion and ensures controlled drug release
Contraindications apply. Read the instructions for use or consult a specialist.
Specifications
| Drug coating | Everolimus |
|---|---|
| Nominal pressure (NP) | 8 atm |
| Rated burst pressure (RBP) | 16 atm |
| Guidewire compatibility | max 0.014″ |
| Catheter compatibility | 5F |
| Radiopaque markers | Pt-Ir, 2 pcs |
| Balloon material | Nylon/Pebax |
Other devices
All productsRussian stents,
direct from the factory
Availability, size range, tender documents and delivery terms — we reply within one working day.
Request a quote